Client update: Fundraising round opens
Atlantic Healthcare specialises in the acquisition and commercialisation of drugs meeting unmet medical needs of patients managed in the hospital and specialist care environments in Europe and United States, that fall below a commercial threshold of ‘big pharma’. This sector of the healthcare market continues to grow and is one in which the Management Team of Atlantic has vast experience having successfully launched and acquired more than 40 drugs.
Atlantic has raised £4.3m of investment to date to progress and prepare its first product; alicaforsen, which is a unique drug used to treat Inflammatory Bowel Disease (IBD) for full commercialisation.
Mark Donaldson, acting as the company’s Chief Financial Officer, has recently announced that Atlantic plans to raise £500k of expansion capital to take the product into profitability in the second half of 2012. Mark is currently assisting Atlantic with the development of investment material and presentations while also presenting and pitching to potential investors.
Atlantic Healthcare recently appointed Richard Wood as Chairman, who retired from Genus plc in September 2011, after taking them as CEO from a £30m UK turnover company to a £300m FTSE 250 listed company operating in 30 countries.
If you would like more information on Atlantic Healthcare or to understand more on how Mint Consult can help your business, please contact Mark Donaldson on 0845 8057390 or 07940 306900.